Drug Trial Radar · NCT04285827
Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease
Last checked: Nov 19, 2026Latest source record: Sep 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
May 20, 2021
Primary completion
Jul 24, 2023
Study completion Jul 24, 2023
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Feb 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1, first-in-human, multi-center, open-label, single dose cohort study to evaluate the safety and tolerability, pharmacokinetics (PK), exploratory pharmacodynamics (PD), and biomarkers of target engagement of CSL889 following single intravenous (IV) doses in subjects with sickle cell disease (SCD). The study involves sequential dose escalation of cohorts with between-group assessments of key safety and PK variables.
Conditions
- Sickle Cell Disease
Interventions
CSL889Biological
Administered as an IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with treatment-emergent adverse events (TEAEs) by CohortTime frame: Up to 32 days after start of CSL889 infusion
- Percentage of subjects with TEAEs by severity by CohortTime frame: Up to 32 days after start of CSL889 infusion
- Percentage of subjects with TEAEs by causality by CohortTime frame: Up to 32 days after start of CSL889 infusion
Locations
15 sites in 3 countries. Site status is shown where the registry gives one.
University of Illinois Hospital and Health Science Systems
Chicago, Illinois
The Johns Hopkins Hospital
Baltimore, Maryland
University of Minnesota
Minneapolis, Minnesota
Jacobi Medical Center
The Bronx, New York
Brody School of Medicine at East Carolina University
Greenville, North Carolina
Ohio State University
Columbus, Ohio
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Amsterdam UMC Academic Medical Center
Amsterdam, Netherlands
Erasmus University Medical Center
Rotterdam, Netherlands
Liverpool University Hospital
Liverpool, United Kingdom
Guys and St. Thomas
London, United Kingdom
University College London Hospital
London, United Kingdom
Manchester University Hospitals NHS Foundation Trust / Manchester Royal Infirmary
Manchester, United Kingdom
Early Phase Unit
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.